Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
46°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
67.72
-0.14 (-0.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
45
46
Next >
Gilead Sciences Unusual Options Activity
September 20, 2023
Via
Benzinga
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
September 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
September 19, 2023
Good medicines aren't always good business.
Via
The Motley Fool
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
September 18, 2023
Via
Benzinga
Can These 3 Healthcare Dividend Stocks Deliver Income Growth?
September 18, 2023
Healthcare-sector dividend payers Pfizer, Medtronic, and Gilead all boosted shareholder payouts and trade at low multiples relative to potential price gains.
Via
MarketBeat
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,000 Today
September 07, 2023
Via
Benzinga
Where Gilead Sciences Stands With Analysts
September 06, 2023
Via
Benzinga
(GILD) - Analyzing Gilead Sciences's Short Interest
September 05, 2023
Via
Benzinga
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
September 18, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
September 13, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food...
Via
FinancialNewsMedia
Exposures
Product Safety
Time For Gilead Sciences-Heavy ETFs?
September 12, 2023
Gilead Sciences has underperformed the broader market this year by a hefty margin.
Via
Talk Markets
Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment
September 11, 2023
Gilead Sciences Inc (NASDAQ: GILD) revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy.
Via
Benzinga
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
September 10, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
What You Need to Know About Hepatitis C This Recovery Month
September 08, 2023
(BPT) - Hepatitis C (HCV) is often referred to as the 'silent disease' due to silent symptoms that may not appear until years after exposure. In fact, of the more than 2 million Americans who are...
Via
Brandpoint
Exposures
COVID-19
How To Earn $500 A Month From Gilead Sciences Stock
September 08, 2023
Shares of Gilead Sciences, Inc (NASDAQ: GILD) are trading higher during Friday’s trading session, bolstered by the Bank of America Securities bullish outlook on the stock.
Via
Benzinga
Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades
September 08, 2023
BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14,
Via
Benzinga
The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month
September 08, 2023
Gilead shares are on the rise amid an unexpected boon for its HIV treatment business.
Via
Investor's Business Daily
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
September 08, 2023
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are trading higher into Friday’s trading session after Bank of America Securities upgraded the stock, highlighting an underappreciated growth potential in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
September 08, 2023
Via
Benzinga
Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday
September 08, 2023
B of A Securities cut the price target for DigitalOcean Holdings, Inc. (NYSE: DOCN) from $47 to $25. B of A Securities analyst Wamsi Mohan downgraded the stock from Buy to Underperform. DigitalOcean...
Via
Benzinga
Gilead Prices $2 Billion of Senior Unsecured Notes
September 07, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
3 No-Brainer Dividend Stocks to Buy in September
September 02, 2023
Income investors should really like these biopharma stocks with juicy dividends.
Via
The Motley Fool
Nearing Retirement? These Stocks Will Pay You For Life
August 29, 2023
These companies are passive income machines.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
August 28, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
Via
Benzinga
GILD Stock Alert: FDA Approves Gilead Sciences’ Veklury Covid-19 Treatment
August 24, 2023
Gilead Sciences (GILD) stock is on the move Thursday following additional FDA approval for its Veklury Covid-19 treatment.
Via
InvestorPlace
Exposures
COVID-19
Product Safety
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
August 24, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
August 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
August 23, 2023
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus...
Via
Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
August 23, 2023
Roche provided an update from its study in lung cancer using an anti-TIGIT drug.
Via
Investor's Business Daily
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
45
46
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.